Literature DB >> 29223463

Terfenadine metabolism of human cytochrome P450 2J2 containing genetic variations (G312R, P351L and P115L).

Dabin Jeong1, Hyoung-Goo Park1, Young-Ran Lim1, Yejin Lee1, Vitchan Kim1, Myung-A Cho1, Donghak Kim2.   

Abstract

The human cytochrome P450 2J2 is involved in several metabolic reactions, including the oxidation of important therapeutics and epoxidation of endogenous arachidonic acid. At least ten genetic variations of P450 2J2 have been identified, but their effects on enzymatic activity have not been clearly characterized. Here, we evaluated the functional effects of three genetic variations of P450 2J2 (G312R, P351L, and P115L). Recombinant enzymes of wild-type and three variant P450 2J2 were heterologously expressed in Escherichia coli and purified. P450 expression levels in the wild-type and two variants (P351L and P115L) were 142-231 nmol per liter culture, while the G312R variant showed no holoenzyme peak in the CO-binding spectra. Substrate binding titrations to terfenadine showed that the wild-type and two variants displayed Kd values of 0.90-2.2 μM, indicating tight substrate binding affinities. Steady-state kinetic analysis for t-butyl methyl hydroxylation of terfenadine indicated that two variant enzymes had similar kcat and Km values to wild-type P450 2J2. The locations of mutations in three-dimensional structural models indicated that the G312R is located in the I-helix region near the formal active site in P450 2J2 and its amino acid change affected the structural stability of the P450 heme environment.
Copyright © 2017 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Allele; Cytochrome P450; Genetic variation; P450 2J2; Terfenadine

Mesh:

Substances:

Year:  2017        PMID: 29223463     DOI: 10.1016/j.dmpk.2017.10.004

Source DB:  PubMed          Journal:  Drug Metab Pharmacokinet        ISSN: 1347-4367            Impact factor:   3.614


  5 in total

1.  Inhibition of cytochrome P450 2B6 by Astragalus extract mixture HT042.

Authors:  Harim Kim; Yejin Lee; Vitchan Kim; Rowoon Lee; Soo Kyung Bae; Mi-Kyoung Kwak; Sung Hoon Lee; Donghak Kim
Journal:  Toxicol Res       Date:  2019-12-04

2.  Evaluation of Human Liver Microtissues for Drug Screening on Schistosoma mansoni Schistosomula.

Authors:  Flavio C Lombardo; Paolo S Ravaynia; Mario M Modena; Andreas Hierlemann; Jennifer Keiser
Journal:  ACS Infect Dis       Date:  2020-10-26       Impact factor: 5.084

3.  Comparative Study of Chemical Stability of Two H1 Antihistaminic Drugs, Terfenadine and Its In Vivo Metabolite Fexofenadine, Using LC-UV Methods.

Authors:  Anna Gumieniczek; Anna Berecka-Rycerz; Rafał Pietraś; Izabela Kozak; Karolina Lejwoda; Paweł Kozyra
Journal:  J Anal Methods Chem       Date:  2019-04-02       Impact factor: 2.193

4.  Functional Characterization of Pharmcogenetic Variants of Human Cytochrome P450 2C9 in Korean Populations.

Authors:  Myung-A Cho; Jihoon G Yoon; Vitchan Kim; Harim Kim; Rowoon Lee; Min Goo Lee; Donghak Kim
Journal:  Biomol Ther (Seoul)       Date:  2019-11-01       Impact factor: 4.634

5.  Molecular determinant of substrate binding and specificity of cytochrome P450 2J2.

Authors:  Liang Xu; Liao Y Chen
Journal:  Sci Rep       Date:  2020-12-17       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.